An article by Matthew Herper of Forbes.com raises questions about the independence of data safety monitoring boards (DSMBs), and the potential for trials of promising drugs to be stopped too early.
An article by Matthew Herper of Forbes.com raises questions about the independence of data safety monitoring boards (DSMBs), and the potential for trials of promising drugs to be stopped too early.
